
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
T-type Ca++ CP α1H CRISPR/Cas9 KO Plasmid (h) | sc-401147 | 20 µg | $397.00 |
CACNA1H encodes the α1H pore-forming subunit of the CaV3.2 T-type calcium channel, which mediates low-voltage–activated Ca2+ influx that shapes membrane excitability, pacemaker activity, and calcium-dependent gene regulation. By controlling subthreshold oscillations and intracellular Ca2+ transients, CaV3.2 integrates into signaling processes that influence neurotransmitter release, hormone secretion, and activity-dependent transcriptional programs. Altered CACNA1H function has been implicated in disorders of excitability, including epilepsy susceptibility, neuropathic pain mechanisms, and cardiac rhythm phenotypes, and is also studied in cancer cell proliferation and survival contexts. As a nodal ion channel in excitatory signaling networks, CACNA1H is frequently interrogated to dissect calcium entry–dependent pathways and channelome remodeling.
T-type Ca++ CP α1H CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CACNA1H gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CACNA1H together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CACNA1H open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish T-type Ca++ CP α1H protein expression.
This CRISPR knockout system enables efficient generation of CACNA1H-deficient cell models for investigation of T-type Ca++ CP α1H signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.